Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics Inc Cl A (NQ: VERA )

48.34 +1.31 (+2.79%)
Streaming Delayed Price Updated: 2:31 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics Inc Cl A

< Previous 1 2 3 4 5 6 7 Next >
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Vera Therapeutics: Q4 Earnings Insights
Via Benzinga
(VERA) - Analyzing Vera Therapeutics's Short Interest
Via Benzinga
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile. 
Via Benzinga
What's Going On With Vera Therapeutics Stock Today?
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals. 
Via Benzinga
Exposures Product Safety
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week. 
Via Benzinga
Topics Government
Exposures Political
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.